{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:10:10Z","timestamp":1774278610345,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T00:00:00Z","timestamp":1508457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T00:00:00Z","timestamp":1508457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder known for the typical motor features associated. Pathologically, it is characterized by the intracellular accumulation of alpha-synuclein (aSyn) in Lewy bodies and Lewy neurites. Currently, there are no established biochemical markers for diagnosing or for following disease progression, a major limitation for the clinical practice. Posttranslational modifications (PTMs) in aSyn have been identified and implicated on its pathobiology. Since aSyn is abundant in blood erythrocytes, we aimed to evaluate whether PTMs of aSyn in the blood might hold value as a biomarker for PD. We examined 58 patients with PD and 30 healthy age-matched individuals. We found that the levels of Y125 phosphorylated, Y39 nitrated, and glycated aSyn were increased in PD, while those of SUMO were reduced. A combinatory analysis of the levels of these PTMs resulted in an increased sensitivity, with an area under curve (AUC) of 0.843 for PD versus healthy controls, and correlated with disease severity and duration. We conclude that the levels of these selected PTMs hold strong potential as biochemical markers for PD. Ultimately, our findings might facilitate the monitoring of disease progression in clinical trials, opening the possibility for developing more effective therapies against PD.<\/jats:p>","DOI":"10.1038\/s41598-017-14175-5","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T14:40:02Z","timestamp":1508164802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson\u2019s disease"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-9259","authenticated-orcid":false,"given":"Hugo","family":"Vicente Miranda","sequence":"first","affiliation":[]},{"given":"Rafaela","family":"C\u00e1ssio","sequence":"additional","affiliation":[]},{"given":"Leonor","family":"Correia-Guedes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-0376","authenticated-orcid":false,"given":"Marcos Ant\u00f3nio","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Cheg\u00e3o","sequence":"additional","affiliation":[]},{"given":"Elisa","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"M\u00e1rio Miguel","family":"Rosa","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"14175_CR1","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T. D. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord \n                           29, 1583\u20131590, https:\/\/doi.org\/10.1002\/mds.25945 (2014).","journal-title":"Mov Disord"},{"key":"14175_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord \n                           30, 1591\u20131601, https:\/\/doi.org\/10.1002\/mds.26424 (2015).","journal-title":"Mov Disord"},{"issue":"Pt 11","key":"14175_CR3","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag, A. & Quinn, N. Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain \n                           123(Pt 11), 2297\u20132305 (2000).","journal-title":"Brain"},{"key":"14175_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord \n                           22, 41\u201347, https:\/\/doi.org\/10.1002\/mds.21198 (2007).","journal-title":"Mov Disord"},{"key":"14175_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord \n                           23, 2129\u20132170, https:\/\/doi.org\/10.1002\/mds.22340 (2008).","journal-title":"Mov Disord"},{"key":"14175_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord \n                           19, 1020\u20131028, https:\/\/doi.org\/10.1002\/mds.20213 (2004).","journal-title":"Mov Disord"},{"key":"14175_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0074-7742(10)90006-8","volume":"90","author":"A Gaenslen","year":"2010","unstructured":"Gaenslen, A. & Berg, D. Early diagnosis of Parkinson\u2019s disease. Int Rev Neurobiol \n                           90, 81\u201392, https:\/\/doi.org\/10.1016\/S0074-7742(10)90006-8 (2010).","journal-title":"Int Rev Neurobiol"},{"key":"14175_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.parkreldis.2014.04.019","volume":"20","author":"J Joutsa","year":"2014","unstructured":"Joutsa, J., Gardberg, M., Roytta, M. & Kaasinen, V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord \n                           20, 840\u2013844, https:\/\/doi.org\/10.1016\/j.parkreldis.2014.04.019 (2014).","journal-title":"Parkinsonism Relat Disord"},{"key":"14175_CR9","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America \n                           95, 6469\u20136473 (1998).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"14175_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.neuron.2016.05.040","volume":"90","author":"A Singleton","year":"2016","unstructured":"Singleton, A. & Hardy, J. The Evolution of Genetics: Alzheimer\u2019s and Parkinson\u2019s Diseases. Neuron \n                           90, 1154\u20131163, https:\/\/doi.org\/10.1016\/j.neuron.2016.05.040 (2016).","journal-title":"Neuron"},{"key":"14175_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/WCO.0b013e3281e6692b","volume":"20","author":"C Klein","year":"2007","unstructured":"Klein, C. & Lohmann-Hedrich, K. Impact of recent genetic findings in Parkinson\u2019s disease. Current opinion in neurology \n                           20, 453\u2013464, https:\/\/doi.org\/10.1097\/WCO.0b013e3281e6692b (2007).","journal-title":"Current opinion in neurology"},{"key":"14175_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/01.jnen.0000171652.40083.15","volume":"64","author":"CM Muller","year":"2005","unstructured":"Muller, C. M. et al. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. Journal of neuropathology and experimental neurology \n                           64, 623\u2013628 (2005).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"14175_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/nature02261","volume":"426","author":"CM Dobson","year":"2003","unstructured":"Dobson, C. M. Protein folding and misfolding. Nature \n                           426, 884\u2013890, https:\/\/doi.org\/10.1038\/nature02261 (2003).","journal-title":"Nature"},{"key":"14175_CR14","doi-asserted-by":"publisher","first-page":"e2000374","DOI":"10.1371\/journal.pbio.2000374","volume":"15","author":"RM de Oliveira","year":"2017","unstructured":"de Oliveira, R. M. et al. The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol \n                           15, e2000374, https:\/\/doi.org\/10.1371\/journal.pbio.2000374 (2017).","journal-title":"PLoS Biol"},{"key":"14175_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/brain\/awx056","volume":"140","author":"H Vicente Miranda","year":"2017","unstructured":"Vicente Miranda, H. et al. Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain \n                           140, 1399\u20131419, https:\/\/doi.org\/10.1093\/brain\/awx056 (2017).","journal-title":"Brain"},{"key":"14175_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12035-012-8330-5","volume":"47","author":"K Beyer","year":"2013","unstructured":"Beyer, K. & Ariza, A. alpha-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol \n                           47, 509\u2013524, https:\/\/doi.org\/10.1007\/s12035-012-8330-5 (2013).","journal-title":"Mol Neurobiol"},{"key":"14175_CR17","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, S., Miranda, H. V. & Outeiro, T. F. In Molecular and Cellular Therapeutics 245\u2013265 (John Wiley & Sons, Ltd, (2012).","DOI":"10.1002\/9781119967309.ch11"},{"key":"14175_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","volume":"183","author":"A Oueslati","year":"2010","unstructured":"Oueslati, A., Fournier, M. & Lashuel, H. A. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies. Prog Brain Res \n                           183, 115\u2013145, https:\/\/doi.org\/10.1016\/S0079-6123(10)83007-9 (2010).","journal-title":"Prog Brain Res"},{"key":"14175_CR19","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. The Journal of biological chemistry \n                           281, 29739\u201329752, https:\/\/doi.org\/10.1074\/jbc.M600933200 (2006).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR20","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1074\/jbc.M109.081950","volume":"285","author":"MK Mbefo","year":"2010","unstructured":"Mbefo, M. K. et al. Phosphorylation of synucleins by members of the Polo-like kinase family. The Journal of biological chemistry \n                           285, 2807\u20132822, https:\/\/doi.org\/10.1074\/jbc.M109.081950 (2010).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12035-013-8473-z","volume":"48","author":"E Basso","year":"2013","unstructured":"Basso, E. et al. PLK2 modulates alpha-synuclein aggregation in yeast and mammalian cells. Mol Neurobiol \n                           48, 854\u2013862, https:\/\/doi.org\/10.1007\/s12035-013-8473-z (2013).","journal-title":"Mol Neurobiol"},{"key":"14175_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nn1443","volume":"8","author":"L Chen","year":"2005","unstructured":"Chen, L. & Feany, M. B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature neuroscience \n                           8, 657\u2013663, https:\/\/doi.org\/10.1038\/nn1443 (2005).","journal-title":"Nature neuroscience"},{"key":"14175_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb841","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature cell biology \n                           4, 160\u2013164, https:\/\/doi.org\/10.1038\/ncb748 (2002).","journal-title":"Nature cell biology"},{"key":"14175_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnmol.2014.00042","volume":"7","author":"S Tenreiro","year":"2014","unstructured":"Tenreiro, S., Eckermann, K. & Outeiro, T. F. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci \n                           7, 42, https:\/\/doi.org\/10.3389\/fnmol.2014.00042 (2014).","journal-title":"Front Mol Neurosci"},{"key":"14175_CR25","doi-asserted-by":"publisher","first-page":"e1004302","DOI":"10.1371\/journal.pgen.1004302","volume":"10","author":"S Tenreiro","year":"2014","unstructured":"Tenreiro, S. et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson\u2019s disease. PLoS Genet \n                           10, e1004302, https:\/\/doi.org\/10.1371\/journal.pgen.1004302 (2014).","journal-title":"PLoS Genet"},{"key":"14175_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jmcb\/mjr011","volume":"3","author":"Y Liu","year":"2011","unstructured":"Liu, Y., Qiang, M., Wei, Y. & He, R. A novel molecular mechanism for nitrated {alpha}-synuclein-induced cell death. Journal of molecular cell biology \n                           3, 239\u2013249, https:\/\/doi.org\/10.1093\/jmcb\/mjr011 (2011).","journal-title":"Journal of molecular cell biology"},{"key":"14175_CR27","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1074\/jbc.M608126200","volume":"282","author":"Z Qin","year":"2007","unstructured":"Qin, Z. et al. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. The Journal of biological chemistry \n                           282, 5862\u20135870, https:\/\/doi.org\/10.1074\/jbc.M608126200 (2007).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1083\/jcb.201010117","volume":"194","author":"P Krumova","year":"2011","unstructured":"Krumova, P. et al. Sumoylation inhibits alpha-synuclein aggregation and toxicity. The Journal of cell biology \n                           194, 49\u201360, https:\/\/doi.org\/10.1083\/jcb.201010117 (2011).","journal-title":"The Journal of cell biology"},{"key":"14175_CR29","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","volume":"17","author":"OM El-Agnaf","year":"2003","unstructured":"El-Agnaf, O. M. et al. Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. FASEB journal: official publication of the Federation of American Societies for Experimental Biology \n                           17, 1945\u20131947, https:\/\/doi.org\/10.1096\/fj.03-0098fje (2003).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"14175_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour, R. et al. Red blood cells are the major source of alpha-synuclein in blood. Neuro-degenerative diseases \n                           5, 55\u201359, https:\/\/doi.org\/10.1159\/000112832 (2008).","journal-title":"Neuro-degenerative diseases"},{"key":"14175_CR31","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1021\/bi015961k","volume":"41","author":"SM Park","year":"2002","unstructured":"Park, S. M. et al. Stress-induced aggregation profiles of GST-alpha-synuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability. Biochemistry \n                           41, 4137\u20134146 (2002).","journal-title":"Biochemistry"},{"key":"14175_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jnc.12251","volume":"126","author":"H Vicente Miranda","year":"2013","unstructured":"Vicente Miranda, H. et al. Heat-mediated enrichment of alpha-synuclein from cells and tissue for assessing post-translational modifications. J Neurochem \n                           126, 673\u2013684, https:\/\/doi.org\/10.1111\/jnc.12251 (2013).","journal-title":"J Neurochem"},{"key":"14175_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.94","volume":"3","author":"O Marques","year":"2012","unstructured":"Marques, O. & Outeiro, T. F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis \n                           3, e350, https:\/\/doi.org\/10.1038\/cddis.2012.94 (2012).","journal-title":"Cell Death Dis"},{"key":"14175_CR34","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1096\/fj.10-179192","volume":"25","author":"PG Foulds","year":"2011","unstructured":"Foulds, P. G. et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson\u2019s disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology \n                           25, 4127\u20134137, https:\/\/doi.org\/10.1096\/fj.10-179192 (2011).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"14175_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/elps.201200151","volume":"33","author":"K Walpurgis","year":"2012","unstructured":"Walpurgis, K. et al. Validated hemoglobin-depletion approach for red blood cell lysate proteome analysis by means of 2D PAGE and Orbitrap MS. Electrophoresis \n                           33, 2537\u20132545, https:\/\/doi.org\/10.1002\/elps.201200151 (2012).","journal-title":"Electrophoresis"},{"key":"14175_CR36","first-page":"627","volume":"4","author":"K Hajian-Tilaki","year":"2013","unstructured":"Hajian-Tilaki, K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J Intern Med \n                           4, 627\u2013635 (2013).","journal-title":"Caspian J Intern Med"},{"key":"14175_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong, Z. et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease. Brain \n                           133, 713\u2013726, https:\/\/doi.org\/10.1093\/brain\/awq008 (2010).","journal-title":"Brain"},{"key":"14175_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer, B. et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol \n                           10, 230\u2013240, https:\/\/doi.org\/10.1016\/S1474-4422(11)70014-X (2011).","journal-title":"Lancet Neurol"},{"key":"14175_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","volume":"532","author":"B Mollenhauer","year":"2013","unstructured":"Mollenhauer, B. et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett \n                           532, 44\u201348, https:\/\/doi.org\/10.1016\/j.neulet.2012.11.004 (2013).","journal-title":"Neurosci Lett"},{"key":"14175_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda, T. et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease. Biochem Biophys Res Commun \n                           349, 162\u2013166, https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.024 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"14175_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","volume":"3","author":"T Stewart","year":"2015","unstructured":"Stewart, T. et al. Phosphorylated alpha-synuclein in Parkinson\u2019s disease: correlation depends on disease severity. Acta Neuropathol Commun \n                           3, 7, https:\/\/doi.org\/10.1186\/s40478-015-0185-3 (2015).","journal-title":"Acta Neuropathol Commun"},{"key":"14175_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neulet.2015.05.030","volume":"599","author":"X Wang","year":"2015","unstructured":"Wang, X., Yu, S., Li, F. & Feng, T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson\u2019s disease. Neurosci Lett \n                           599, 115\u2013119, https:\/\/doi.org\/10.1016\/j.neulet.2015.05.030 (2015).","journal-title":"Neurosci Lett"},{"key":"14175_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener \n                           11, 7, https:\/\/doi.org\/10.1186\/s13024-016-0072-9 (2016).","journal-title":"Mol Neurodegener"},{"key":"14175_CR44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1074\/mcp.M114.040576","volume":"14","author":"M Shi","year":"2015","unstructured":"Shi, M. et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics \n                           14, 544\u2013555, https:\/\/doi.org\/10.1074\/mcp.M114.040576 (2015).","journal-title":"Mol Cell Proteomics"},{"key":"14175_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1073\/pnas.0711053105","volume":"105","author":"OS Gorbatyuk","year":"2008","unstructured":"Gorbatyuk, O. S. et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America \n                           105, 763\u2013768, https:\/\/doi.org\/10.1073\/pnas.0711053105 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"14175_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","volume":"287","author":"R Borghi","year":"2000","unstructured":"Borghi, R. et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson\u2019s disease and normal subjects. Neurosci Lett \n                           287, 65\u201367 (2000).","journal-title":"Neurosci Lett"},{"key":"14175_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels, T., Choi, J. G. & Selkoe, D. J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature \n                           477, 107\u2013110, https:\/\/doi.org\/10.1038\/nature10324 (2011).","journal-title":"Nature"},{"key":"14175_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8314","volume":"6","author":"U Dettmer","year":"2015","unstructured":"Dettmer, U. et al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun \n                           6, 7314, https:\/\/doi.org\/10.1038\/ncomms8314 (2015).","journal-title":"Nat Commun"},{"key":"14175_CR49","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid, A. W., Fauvet, B., Moniatte, M. & Lashuel, H. A. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics \n                           12, 3543\u20133558, https:\/\/doi.org\/10.1074\/mcp.R113.032730 (2013).","journal-title":"Mol Cell Proteomics"},{"key":"14175_CR50","doi-asserted-by":"publisher","unstructured":"Vicente Miranda, H., El-Agnaf, O. M. & Outeiro, T. F. Glycation in Parkinson\u2019s disease and Alzheimer\u2019s disease. Mov Disord, https:\/\/doi.org\/10.1002\/mds.26566 (2016).","DOI":"10.1002\/mds.26566"},{"key":"14175_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/path.2682","volume":"221","author":"H Vicente Miranda","year":"2010","unstructured":"Vicente Miranda, H. & Outeiro, T. F. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol \n                           221, 13\u201325, https:\/\/doi.org\/10.1002\/path.2682 (2010).","journal-title":"J Pathol"},{"key":"14175_CR52","doi-asserted-by":"publisher","first-page":"12334","DOI":"10.1074\/jbc.M110414200","volume":"277","author":"BH Ahn","year":"2002","unstructured":"Ahn, B. H. et al. alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. The Journal of biological chemistry \n                           277, 12334\u201312342, https:\/\/doi.org\/10.1074\/jbc.M110414200 (2002).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR53","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1074\/jbc.M010316200","volume":"276","author":"CE Ellis","year":"2001","unstructured":"Ellis, C. E., Schwartzberg, P. L., Grider, T. L., Fink, D. W. & Nussbaum, R. L. alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. The Journal of biological chemistry \n                           276, 3879\u20133884, https:\/\/doi.org\/10.1074\/jbc.M010316200 (2001).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR54","doi-asserted-by":"publisher","unstructured":"Nakamura, T., Yamashita, H., Takahashi, T. & Nakamura, S. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun \n                           280, 1085\u20131092, doi:10.1006\/bbrc.2000.4253 (2001).","DOI":"10.1006\/bbrc.2000.4253"},{"key":"14175_CR55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1096\/fj.01-0517fje","volume":"16","author":"A Negro","year":"2002","unstructured":"Negro, A., Brunati, A. M., Donella-Deana, A., Massimino, M. L. & Pinna, L. A. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology \n                           16, 210\u2013212, https:\/\/doi.org\/10.1096\/fj.01-0517fje (2002).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"14175_CR56","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest \n                           119, 3257\u20133265, doi:10.1172\/JCI39088 (2009).","DOI":"10.1172\/JCI39088"},{"key":"14175_CR57","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1021\/cn5002254","volume":"5","author":"J Kosten","year":"2014","unstructured":"Kosten, J. et al. Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. ACS Chem Neurosci \n                           5, 1203\u20131208, https:\/\/doi.org\/10.1021\/cn5002254 (2014).","journal-title":"ACS Chem Neurosci"},{"key":"14175_CR58","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","volume":"23","author":"AL Mahul-Mellier","year":"2014","unstructured":"Mahul-Mellier, A. L. et al. c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson\u2019s disease. Hum Mol Genet \n                           23, 2858\u20132879, https:\/\/doi.org\/10.1093\/hmg\/ddt674 (2014).","journal-title":"Hum Mol Genet"},{"key":"14175_CR59","doi-asserted-by":"publisher","first-page":"9919","DOI":"10.1074\/jbc.M510127200","volume":"281","author":"V Dorval","year":"2006","unstructured":"Dorval, V. & Fraser, P. E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. The Journal of biological chemistry \n                           281, 9919\u20139924, https:\/\/doi.org\/10.1074\/jbc.M510127200 (2006).","journal-title":"The Journal of biological chemistry"},{"key":"14175_CR60","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.290.5493.985","volume":"290","author":"BI Giasson","year":"2000","unstructured":"Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science \n                           290, 985\u2013989 (2000).","journal-title":"Science"},{"key":"14175_CR61","doi-asserted-by":"publisher","first-page":"e9956","DOI":"10.1371\/journal.pone.0009956","volume":"5","author":"Z Yu","year":"2010","unstructured":"Yu, Z. et al. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One \n                           5, e9956, https:\/\/doi.org\/10.1371\/journal.pone.0009956 (2010).","journal-title":"PLoS One"},{"key":"14175_CR62","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00702-013-0972-6","volume":"120","author":"G Caranci","year":"2013","unstructured":"Caranci, G. et al. Gender differences in Parkinson\u2019s disease: focus on plasma alpha-synuclein. J Neural Transm (Vienna) \n                           120, 1209\u20131215, https:\/\/doi.org\/10.1007\/s00702-013-0972-6 (2013).","journal-title":"J Neural Transm (Vienna)"},{"key":"14175_CR63","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/brain\/awr015","volume":"134","author":"I Devic","year":"2011","unstructured":"Devic, I. et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease. Brain \n                           134, e178, https:\/\/doi.org\/10.1093\/brain\/awr015 (2011).","journal-title":"Brain"},{"key":"14175_CR64","doi-asserted-by":"publisher","first-page":"121ra120","DOI":"10.1126\/scitranslmed.3002566","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. Phosphorylated alpha-synuclein in Parkinson\u2019s disease. Sci Transl Med \n                           4, 121ra120, https:\/\/doi.org\/10.1126\/scitranslmed.3002566 (2012).","journal-title":"Sci Transl Med"},{"key":"14175_CR65","unstructured":"Abramoff, M. D., Magelhaes, P. J. & Ram, S. J. Image Processing with ImageJ. Biophotonics Int \n                           11 (2004)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14175-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:29:08Z","timestamp":1671798548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14175-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14175"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14175-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]},"assertion":[{"value":"27 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13713"}}